Acrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $19.00 by Analysts at HC Wainwright

Acrivon Therapeutics (NASDAQ:ACRV - Free Report) had its price target decreased by HC Wainwright from $22.00 to $19.00 in a research note issued to investors on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Acrivon Therapeutics' Q1 2025 earnings at ($0.63) EPS, Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.77) EPS, FY2027 earnings at ($2.31) EPS, FY2028 earnings at ($1.96) EPS and FY2029 earnings at ($1.25) EPS.

Other equities research analysts also recently issued reports about the stock. Cantor Fitzgerald began coverage on shares of Acrivon Therapeutics in a research report on Friday, January 31st. They issued an "overweight" rating on the stock. KeyCorp began coverage on Acrivon Therapeutics in a report on Friday, January 31st. They issued an "overweight" rating on the stock. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $23.17.

Acrivon Therapeutics Stock Performance

Shares of Acrivon Therapeutics stock traded down $0.28 on Wednesday, reaching $2.24. The company had a trading volume of 434,076 shares, compared to its average volume of 262,128. Acrivon Therapeutics has a 52-week low of $2.14 and a 52-week high of $11.90. The firm's 50 day moving average price is $5.35 and its two-hundred day moving average price is $6.52. The firm has a market cap of $69.74 million, a PE ratio of -0.83 and a beta of 0.85.

Remove Ads

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.09. As a group, sell-side analysts predict that Acrivon Therapeutics will post -2.49 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Barclays PLC raised its stake in Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company's stock worth $233,000 after acquiring an additional 11,273 shares in the last quarter. State Street Corp grew its holdings in shares of Acrivon Therapeutics by 26.4% during the third quarter. State Street Corp now owns 225,896 shares of the company's stock worth $1,581,000 after purchasing an additional 47,233 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Acrivon Therapeutics by 548.3% during the third quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company's stock worth $238,000 after purchasing an additional 28,748 shares in the last quarter. Exome Asset Management LLC purchased a new stake in shares of Acrivon Therapeutics in the 3rd quarter valued at about $817,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Acrivon Therapeutics in the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 71.62% of the company's stock.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.